Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487098 | 0.88 | NISCH (0.32) | ALDH1A1MAPTHTTBUB1KDM4E | |
| SCHEMBL6487101 | 0.88 | NISCH (0.32) | ALDH1A1MAPTHTTBUB1KDM4E | |
| SCHEMBL6491124 | 0.83 | PTGES (0.40) | ALDH1A1MAPTHTTACHEKDM4E | |
| SCHEMBL6491123 | 0.83 | PTGES (0.40) | ALDH1A1MAPTHTTACHEKDM4E | |
| SCHEMBL6489539 | 0.78 | ALDH1A1 (0.40) | ALDH1A1MAPTHTTKDM4ELMNA | |
| SCHEMBL6487319 | 0.77 | ADRA2A (0.41) | ALDH1A1BUB1KDM4EPARP1PARP2 | |
| SCHEMBL6496897 | 0.74 | HTR2A (0.37) | ALDH1A1MAPTHTTACHE | |
| SCHEMBL6496901 | 0.74 | HTR2A (0.37) | ALDH1A1MAPTHTTACHE | |
| SCHEMBL6497443 | 0.74 | MAP3K14 (0.40) | ALDH1A1MAPTHTT | |
| SCHEMBL6488757 | 0.74 | MAP3K14 (0.40) | ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951881-B2 | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | ALDH1A1 1019/4885MAPT 1293/4885HTT 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.